Analyst Sean Laaman from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals and increased the price target to $25.00 from $24.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sean Laaman has given his Hold rating due to a combination of factors surrounding ACADIA Pharmaceuticals. The company’s recent performance shows a stable patient count for Daybue in the U.S., despite some disruption from a new customer model. The U.S. market penetration is around 40%, with significant growth potential in the community setting, as evidenced by the high rate of new prescriptions from community physicians.
Moreover, while the persistency rates for Daybue remain strong, the company’s revenue includes contributions from international markets, indicating a broader adoption. The recent expansion of the field force has led to the highest rate of referrals since the launch, and management expects continued growth in patient numbers through 2026 and beyond. Despite these positive indicators, the financial results were only modestly revised higher, suggesting a cautious outlook for the stock in the near term.
In another report released yesterday, Bank of America Securities also reiterated a Hold rating on the stock with a $27.00 price target.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ACAD in relation to earlier this year.